Real-World Evidence

Real-world evidence is clinical evidence derived from routine healthcare data rather than tightly controlled trials. It helps show how treatments and outcomes behave across broader, messier patient populations. In practice, it is valuable because it complements trial data, but it also demands careful interpretation of study design, context, and measured effect.

Expanded Definition

Real-world evidence, often abbreviated as RWE, refers to clinical evidence generated from routine care settings, such as electronic health records, claims data, registries, patient-reported outcomes, and other healthcare data sources. It is distinct from evidence produced in tightly controlled randomised trials because it reflects how interventions perform across varied populations, comorbidities, adherence patterns, and care environments. That broader scope is why RWE is increasingly used for post-market assessment, safety surveillance, health technology assessment, and comparative effectiveness questions.

Its value depends heavily on study design, data quality, confounding control, and transparent methods. RWE is not automatically “more real” or more reliable than trial data; it is different evidence with different strengths and limitations. In practice, it is most defensible when the data-generating process, inclusion criteria, and analytic assumptions are explicit, and when the evidence is interpreted alongside established clinical and regulatory standards. For governance context, healthcare organisations often align evidence handling and data stewardship with NIST Cybersecurity Framework 2.0 principles for risk management. The most common misapplication is treating observational data as if it had trial-level causal certainty, which occurs when selection bias and missing context are ignored.

Examples and Use Cases

Implementing RWE rigorously often introduces methodological and governance overhead, requiring organisations to weigh broader applicability against the risk of biased conclusions.

• Comparing outcomes for two therapies using claims and registry data to understand how they perform in routine practice, not just in trial populations.
• Assessing long-term safety signals after approval, especially where rare adverse events may not have appeared in pre-market studies.
• Evaluating treatment adherence and persistence in populations with multiple comorbidities, where trial eligibility criteria would have excluded many patients.
• Supporting payer or health technology assessment decisions with evidence drawn from healthcare operations, outcomes databases, and observational cohorts.
• Linking evidence generation to data governance controls so patient data handling, access review, and provenance remain auditable, in line with broader operational risk practices described by NIST Cybersecurity Framework 2.0.

RWE is also used when researchers want to study subgroups that are underrepresented in clinical trials, such as older adults, people with multiple conditions, or patients in under-resourced care settings. In those cases, the evidence can be highly informative, but only if analysts acknowledge missingness, coding variation, and site-to-site differences in data capture. That is why usage in the industry is still evolving: some organisations treat RWE as a supplement to trials, while others use it to inform regulatory and reimbursement decisions more directly.

Why It Matters for Security Teams

For security and governance teams in healthcare and life sciences, RWE matters because the evidence is only as trustworthy as the data pipeline that produces it. If patient data is incomplete, altered, duplicated, or accessed outside authorised workflows, the resulting evidence can be misleading even when the statistical analysis is technically sound. That makes data integrity, provenance, access control, and auditability central concerns rather than back-office details. Organisations handling RWE often need to think in terms of confidentiality, integrity, and traceability, not just analytics.

This is where identity and access governance intersect with research operations: privileged access to registries, warehouse exports, and analytics environments must be tightly controlled, and identity assurance becomes part of evidence quality. A compromised account or weakly governed service credential can distort datasets silently, which is why evidence programs increasingly depend on disciplined control environments and data lifecycle oversight. The security discipline around these workflows aligns with the intent of NIST Cybersecurity Framework 2.0. Organisations typically encounter the operational impact only after a dataset is challenged, at which point real-world evidence becomes impossible to defend without reconstructing provenance and access history.

Related resources from NHI Mgmt Group

• Why do pentest findings often fail to reduce real-world risk?
• Why do push-based MFA methods fail in real-world attacks?
• Why do sandbox tests often miss real-world identity risk in financial data sharing?
• How can organisations know whether access reviews are producing real governance evidence?